Ixabepilone for the treatment of endometrial cancer

References

• American Cancer Society. Cancer facts & figs. 2016. Atlanta: American Cancer Society; 2016.
   Google Scholar
• Creutzberg CL, Van Stiphout RG, Nout RA, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys. 2015;91(3):530–539.
   PubMed Web of Science ®Google Scholar
• Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lympho- vascular space invasion. Int J Gynecol Cancer. 2013;23:98–104.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Guidelines Uterine Neoplasm Version 2. 2016. [http://www.nccn.org/].
   Google Scholar
• Hogberg T, Signorelli M, De Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer. 2010;46(13):2422–2431.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109(2):250–254.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase III non inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstract]. Gynecol Oncol. 2012;125:771.
   Web of Science ®Google Scholar
• Vale CL, Tierney J, Bull SJ, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2012;8:CD003915.
   PubMedGoogle Scholar
• Garcia AA, Blessing JA, Nolte S, et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008;111(1):22–26.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 1;29(16):2259–2265.
   PubMed Web of Science ®Google Scholar
• Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007 Dec;33(8):688–703.
   PubMed Web of Science ®Google Scholar
• Akbari V, Moghim S, Reza Mofid M. Comparison of epothilone and taxol binding in yeast tubulin using molecular modeling. Avicenna J Med Biotechnol. 2011;3(4):167–175.
   PubMedGoogle Scholar
• Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008;63:157–66.
   PubMed Web of Science ®Google Scholar
• Federal Drug Administration. FDA approves ixempra for advanced breast cancer patients [cited 2007 Oct 22]. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109015.htm.
   Google Scholar
• Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy- naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724–8729.
   PubMed Web of Science ®Google Scholar
• Burtness BA, Manola J, Axelrod R, et al. Eastern Cooperative Oncology Group. A randomized phase II study of ixabepilone (BMS-247550) given daily 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008;19:977–983.
   PubMed Web of Science ®Google Scholar
• Roque DM, Ratner ES, Silasi DA, et al. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: a retrospective review. Gynecol Oncol. 2015;137(3):392–400.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/ carboplatin/ bevacizumab, paclitaxel/ carboplatin/ temsirolimus and ixabepilone/ carboplatin/ bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33. (suppl; abstr 5500)
   PubMed Web of Science ®Google Scholar
• McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23.
   PubMed Web of Science ®Google Scholar
• IXEMPRA packaging information. [cited Nov, 2012]. Available from http://packageinserts.bms.com/pi/pi_ixempra.pdf.
   Google Scholar
• Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin- targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(Suppl. 5):v9–15.
   PubMed Web of Science ®Google Scholar
• McDaid HM, Mani S, Shen HJ, et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002;8(7):2035–2043.
   PubMed Web of Science ®Google Scholar
• Zhuang SH, Hung YE, Hung L, et al. Evidence for micro- tubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res. 2007;13(24):7480–7486.
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7(5):1429–1437.
   PubMed Web of Science ®Google Scholar
• Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63(2):201–212.
   PubMed Web of Science ®Google Scholar
• Puhalla S, Brufsky A. Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics. 2008;2(3):505–515.
   PubMedGoogle Scholar
• Goel S, Cohen M, Cömezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701–2709.
   PubMed Web of Science ®Google Scholar
• Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer. 2007 Apr;7(7):543–549.
   PubMed Web of Science ®Google Scholar
• De Luca A, D’Alessio A, Maiello MR, et al. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1177–85.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol. 2008;61:751–758. Epub 27 Jun 2007
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003;21:1866–1873.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Burris HR, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25:1082–1088.
   PubMed Web of Science ®Google Scholar
• Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27(19):3104–3108.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, Lagasse LD, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol. 1984;7:253–256.
   PubMed Web of Science ®Google Scholar
• Lee FY, Lewin A, Wen M, et al. Anti-angiogenic synergy with ixabepilone: translation of preclinical studies to the clinical setting. Cancer Res. 2009;69(24Suppl. 3):206. (abstract)
   Google Scholar
• Vahdat L:. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist. 2008;13:214–221.
   PubMed Web of Science ®Google Scholar
• Fornier MN. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer. 2007;7:757–763.
   PubMed Web of Science ®Google Scholar